If You Invested in SIRONA BIOCHEM CORP (SRBCF)

Sirona Biochem Corp. (OTC: SRBCF) is described in its public communications as a cosmetic ingredient and drug discovery company operating in the biotechnology field. The company is associated with research and development activities in biotechnology and is part of the broader professional, scientific, and technical services sector. Sirona Biochem emphasizes a proprietary platform technology that focuses on stabilizing carbohydrate molecules with the goal of improving efficacy and safety for cosmetic and therapeutic applications. New compounds developed through this platform are patented with the stated aim of maximizing revenue potential.

Across multiple corporate updates, Sirona Biochem explains that its business model centers on developing active ingredients and licensing these compounds to other companies. According to the company, its compounds are licensed to cosmetics and pharmaceutical companies, as well as other leading companies around the world, in return for licensing fees, milestone payments or milestone fees, and ongoing royalty payments. This positions Sirona Biochem as a research and development specialist that seeks to generate value by creating proprietary molecules and partnering with industry participants for commercialization.

Core scientific focus and platform technology

In its news releases, Sirona Biochem repeatedly highlights a proprietary platform technology that is used to stabilize carbohydrate molecules. The company states that this stabilization is intended to improve the efficacy and safety of active ingredients used in cosmetic and dermatology applications, as well as in drug discovery. By focusing on carbohydrate-based molecules, Sirona Biochem presents itself as a biotechnology company with a specific scientific niche. The company also notes that its research and development unit, the laboratory TFChem, is located in France and has received multiple French national scientific awards, as well as European Union and French government grants.

Sirona Biochem communicates that its scientific team works on a pipeline of projects in cosmetic and therapeutic skincare, and has also referenced work in areas such as antiviral projects and SGLT2 diabetes-related research. At various times, the company has indicated that some projects are public while others remain confidential for intellectual property reasons. This reflects a model where discovery and early-stage development are central, with intellectual property protection viewed as a key component of potential future value.

Cosmetic and dermatology active ingredients

In more recent updates, Sirona Biochem states that it is focusing on innovative cosmetic and dermatology active ingredients. A major area of emphasis in its communications is the anti-aging skincare ingredient GlycoProteMim™, which the company also refers to by its development code TFC-1326. Sirona Biochem reports that it has trademarked TFC-1326 as GlycoProteMim and describes this as a strategic branding decision intended to distinguish the ingredient in the anti-aging market.

The company has described GlycoProteMim as a novel anti-aging compound developed under the direction of its Chief Scientific Officer using chemistry inspired by nature. Sirona Biochem states that GlycoProteMim has been clinically validated as a significant development in non-invasive anti-aging skincare and that it offers rejuvenation benefits for aged skin. In its communications, the company characterizes GlycoProteMim as safe, effective, and easy to use, and presents it as a candidate to complement or serve as an alternative to other aesthetic options, depending on consumer preferences. Sirona Biochem also notes that it has initiated trademark filings for GlycoProteMim with relevant authorities.

Subsidiaries and laboratory operations

Sirona Biochem’s research and development activities are closely linked to its wholly owned laboratory subsidiary TFChem in France. The company has repeatedly stated that TFChem is the recipient of multiple French national scientific awards and European Union and French government grants. TFChem has been involved in the development and formulation of key compounds, including TFC-1067 and GlycoProteMim.

In an update to shareholders dated August 1, 2025, Sirona Biochem reported that, in light of limited financing options, it made the decision to allow for the orderly liquidation of its wholly owned subsidiary TFChem in accordance with French bankruptcy regulations. The company stated that all laboratory operations had ceased and that the facility was permanently closed. This marks a significant change in the operational structure described in earlier communications, where TFChem was presented as an active R&D laboratory.

Commercialization strategy and Sirona Laboratories™

Sirona Biochem has outlined a commercialization strategy for GlycoProteMim that includes both direct commercialization and licensing. In several news releases, the company describes the creation of a wholly owned subsidiary, Sirona Laboratories™, which is dedicated to commercializing GlycoProteMim and related skincare products. Sirona Biochem indicates that it intends to maintain majority ownership of this subsidiary.

The company explains that Sirona Laboratories is intended to provide a more streamlined path to market by focusing specifically on the commercial development of GlycoProteMim-based products. Sirona Biochem has described plans for Sirona Laboratories to launch consumer products containing GlycoProteMim in Europe and North America, with potential expansion to other markets and exploration of licensing opportunities in additional regions. The company has also communicated that Sirona Laboratories is expected to serve as a platform for future cosmeceutical products developed by its scientific team.

Licensing agreements and partnerships

Sirona Biochem has disclosed several notable relationships in its public communications. The company states that it entered into an exclusive global licensing agreement with Allergan Aesthetics for the compound TFC-1067, which is described as a cosmetic ingredient. In earlier updates, Sirona Biochem reported that Allergan was progressing with the integration of TFC-1067 into its product lineup under this global licensing agreement. Later, in the August 1, 2025 update, Sirona Biochem reported that it had been informed that Allergan Aesthetics would not be proceeding with the license agreement regarding the commercialization of TFC-1067.

The company has also reported collaborations and advisory relationships with external partners. For example, Sirona Biochem announced a partnership with Stonegate Healthcare Partners, a corporate advisory firm, to evaluate GlycoProteMim and assess its market potential within the global anti-aging skincare industry. In another release, Sirona Biochem described a partnership with Global Beauty Consulting – Cosmetics Laboratory (GBC), under which GBC is developing a premium formulation for GlycoProteMim in anticipation of a product launch. The company has also mentioned working with other external specialists, such as a South Korean label design specialist and a Paris-based facialist, in connection with product development and branding efforts.

Financing, corporate challenges, and strategic reviews

Sirona Biochem’s news releases also provide insight into its financial and corporate context. The company has discussed non-brokered private placements intended to raise working capital, as well as efforts to secure strategic funding from private equity funds and other investors. In several communications, Sirona Biochem notes that financing conditions in the small-cap marketplace have been challenging and that its traditional brokers have had reduced fundraising capabilities.

In the August 1, 2025 shareholder update, Sirona Biochem reported that a convertible debenture financing announced earlier did not attract sufficient investor participation. The company also described entering into an investment agreement with Promura GmbH, following due diligence, but stated that the funds under this agreement were never received and that it had concluded the investment would not materialize. The same update notes that Sirona Biochem faced ongoing financial pressures and that a cease trade order was issued on March 7, 2025. The company also states that management in Vancouver had operated without salary for an extended period and had personally contributed funds to sustain essential operations.

Earlier communications describe a strategic review of the company’s management, organizational structure, project pipeline, financial position, and stock exchange listings. Sirona Biochem has indicated an intention to review and adjust its organizational structure in both its Vancouver headquarters and its research facility in France, and to seek greater visibility among institutional investors and within the biotech community.

Pipeline and areas of research

Sirona Biochem’s communications refer to a pipeline that includes cosmetic and therapeutic skincare projects, as well as other research areas. In addition to GlycoProteMim and TFC-1067, the company has mentioned work on an antiviral library and an SGLT2 diabetes project. It has also referenced potential projects in cellulite, wound care, and keloid treatments, and has indicated that some of these areas may be advanced through Sirona Laboratories as cosmeceutical products.

The company emphasizes that its scientific team is engaged in discovering new opportunities and that some projects remain confidential until intellectual property can be secured. At the same time, Sirona Biochem has communicated that, at certain points, its primary focus has been on developments within the aesthetic and cosmetic skincare space, reflecting a strategic concentration on areas where it perceives significant commercial potential.

Status considerations and risk context

Based on the available news, Sirona Biochem has faced significant financial and operational challenges, including unsuccessful financings, the non-completion of an expected investment agreement, the liquidation of its TFChem subsidiary, and a cease trade order. The company has acknowledged that the commercial potential of its proprietary technologies remains uncertain and has stated that it is evaluating structural and financial options that could, if feasible, support their future development.

At the same time, Sirona Biochem continues to describe itself as a cosmetic ingredient and drug discovery company with a proprietary platform technology, and it has outlined strategies for the commercialization of GlycoProteMim and other potential skincare products through Sirona Laboratories and licensing arrangements. The information presented in its public communications reflects both the company’s scientific ambitions and the financial and operational risks it has identified.